Program Book

Methods. A retrospective study of 15 patients with pure iris melanoma
treated with Ruthenium-106 plaque radiotherapy from June 1998 to June
2006. The main outcome measures were tumour control and ocular
complications.
Results. Of the 15 patients, 8 had biopsy-proven melanoma (6 incisional
and 2 excisional biopsies). In the remaining 7, patients enlargement
of the lesion was documented. The median follow-up was 96 months
(ranging from 14 months to 12 years). Common radiation-related
complications included cataract in 9 (60%) patients, dry eyes in 3(20%)
patients and elevated intraocular pressure in 4 (27%) patients. Vision
was preserved in 80% of patients. Local tumour control was obtained
in all patients.
Conclusions. Ruthenium-106 plaque radiotherapy is an effective
treatment for primary malignant iris melanoma , resulting in excellent
local control with preservation of vision. Main complications included
cataract ,dry eyes and glaucoma.
Financial disclosure. None
1849 UM22
RUTHENIUM BRACHYTHERAPY WITH THE 10 MM
PLAQUE FOR SMALL POSTERIOR CHOROIDAL MELA-
NOMAS
Tero Kivelä, Susanna Salkola, Sebastian Eskelin, Jorma Heikkonen
(tero.kivela@helsinki.fi)
Department of Ophthalmology and Oncology, Helsinki University Central
Hospital, Helsinki, Finland
Purpose. To assess tumour control and morbidity after brachytherapy
with 10 mm ruthenium plaques for small posterior choroidal melanomas.
Methods. In 1998-2009, forty-five consecutive choroidal melanomas were
scheduled for irradiation with the 10 mm plaque. The median height and
LBD were 1.9 (range, 0.4-5.2) and 7.0 (range, 3.3-9.6) mm, respectively.
All tumours were T1aN0M0, Stage I (7th edition; 11 were T2, 6th edition).
Median distance was 3.0 mm (range, 0-7.5) from disk and 2.0 mm (range,
0-8.5) from foveola. The anterior margin was posterior to the equator for
all except one. Median dose was 116 Gy (range, 80-194) to apex and 327
Gy (range, 201-824) to base.
Results. Four marginal recurrences developed a median of 1.4 years
(range, 0.6-3.0) after irradiation; two were also vertical (apical and basal
dose was 126-129 Gy and 266-324 Gy, respectively; median distance
from disk 1.4 mm; range, 0.4-3.8). Kaplan-Meier recurrence rate was 10%
(95% CI, 4-24) by 5 years. No patient developed signs of metastases. Six
patients, one with a prior recurrence, died a median of 4.2 years (range,
0.28-8.6) after treatment; 5-year all-cause mortality was 12% (95% CI
5-29). Regarding complications by 5 years, 50% (95% CI, 32-66) were
free of any maculopathy and 97% (95% CI, 80-100) were free or optic
neuropathy. Mean visual acuity was 0.8 at diagnosis and 0.63 at 5 years,
based on logMAR.
Conclusions. The results compare favourably with an recurrence rate of
0.25 by 5 years after transpupillary thermotherapy for tumours of similar
size and location.
Financial disclosure. None
63 UM23
REGRESSION OF UVEAL MELANOMA FOLLOWING
IODINE 125 PLAQUE RADIOTHERAPY: PREDICTIVE
FACTORS AND CORRELATION WITH METASTASIS
UVEAL MELANOMA
Abstracts
103
Hakan Demirci, Fiorella Saponara, Adam Khan, Leslie Niziol,Grant
Comer,David Musch (hdemirci@med.umich.edu)
W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI
Purpose. To analysis uveal melanoma regression following iodine 125
plaque radiotherapy, and evaluate its predictive factors and correlation
with metastasis.
Methods. Retrospective analysis of 124 eyes with > 3 years follow-up
Results. By 50% increase in follow-up time, decrease in tumor thickness
was 0.99 mm, 0.57 mm and 0.3 mm for tumors with initial thickness >
8 mm, 3-8 mm and